Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content
Fig. 2 | Clinical Proteomics

Fig. 2

From: Glial fibrillary acidic protein, neurofilament light, matrix metalloprotease 3 and fatty acid binding protein 4 as non-invasive brain tumor biomarkers

Fig. 2

Comparison of genetic and proteomic markers. Genetic markers of gliomas and their relationship to plasma concentrations of the four biomarkers shown (FABP4, GFAP, MMP3, NEFL). The figure shows the median (horizontal lines), and interquartile range. Means are indicated with an ‘x’. Significance levels for independent t tests are shown at the top of each plot and have not been adjusted for multiple comparisons. Despite several differences indicating statistical significance, these differences are generally small. For more details of patient genetic status see also Supplementary Table 5. For GFAP, the most important differences (P = < 0.01) were between GFAP and IDH1 status, ATRX expression, MGMT promoter methylation, TERT promoter mutation, and CDKN2A/B p16 and 1p/19q co-deletion

Back to article page

Clinical Proteomics

ISSN: 1559-0275